List of works - Peter G. Lurie

Addressing prescription opioid overdose: data support a comprehensive policy approach

scientific article

Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products

scientific article published on 01 February 2019

Association of Appearance of Conflicts of Interest With Voting Behavior at FDA Advisory Committee Meetings-A Cross-sectional Study

scientific article published on 2 May 2017

Caffeinated energy drinks: adverse event reports to the US Food and Drug Administration and the National Poison Data System, 2008 to 2015

scientific article published on 18 July 2019

Description of a research-based health activism curriculum for medical students

scientific article published in December 2006

Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing

scientific article published on 25 January 2016

Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting

scientific article published on 9 September 2016

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review

scientific article published on 30 December 2019

Expanded Access to Opioid Overdose Intervention: Research, Practice, and Policy Needs

scientific article published on January 1, 2013

Expanded access to investigational drugs

scientific article published in April 2015

Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings

scientific article published in The Journal of the American Medical Association

Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.

scientific article published on 30 October 2006

Harnessing the Power of Food Labels for Public Health

scientific article published on 20 February 2019

How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?

scientific article published in October 2017

Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment.

scientific article published on 17 May 2018

Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013

scientific article published on 18 February 2016

Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018

scientific article published on 29 September 2020

Left to their own devices: breakdowns in United States medical device premarket review

scientific article

Misleading data analyses in salmeterol (SMART) study

scientific article

Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing.

scientific article published on 8 May 2017

Overview of FDA's Expanded Access Program for Investigational Drugs

scientific article

Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota

scientific article

Preventing prescription opioid abuse--reply

scientific article published in March 2015

Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration

scientific article published on 03 June 2019

Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013.

scientific article published on 15 May 2017

Suboptimum use of FDA drug advisory committees

scientific article published on 01 December 2006

Suggestions for Improving Conflict of Interest Processes in the US Food and Drug Administration Advisory Committees-Past Imperfect

scientific article published on 01 July 2018

Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017

scientific article published on 09 December 2019

The US Food and Drug Administration's tentative approval process and the global fight against HIV.

scientific article published in December 2017

Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.

scientific article

US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs

scientific article published on 17 August 2015

Updated Estimates of Pharmaceutical Company Payments to Physicians in Vermont

scientific article published in The Journal of the American Medical Association

Violations of exhibiting and FDA rules at an American Psychiatric Association annual meeting.

scientific article

List of works by Peter G. Lurie

Addressing prescription opioid overdose: data support a comprehensive policy approach

Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products

Association of Appearance of Conflicts of Interest With Voting Behavior at FDA Advisory Committee Meetings-A Cross-sectional Study

Caffeinated energy drinks: adverse event reports to the US Food and Drug Administration and the National Poison Data System, 2008 to 2015

Description of a research-based health activism curriculum for medical students

Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing

Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review

Expanded Access to Opioid Overdose Intervention: Research, Practice, and Policy Needs

Expanded access to investigational drugs

Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings

Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.

Harnessing the Power of Food Labels for Public Health

How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?

Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment.

Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013

Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018

Left to their own devices: breakdowns in United States medical device premarket review

Misleading data analyses in salmeterol (SMART) study

Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing.

Overview of FDA's Expanded Access Program for Investigational Drugs

Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota

Preventing prescription opioid abuse--reply

Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration

Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013.

Suboptimum use of FDA drug advisory committees

Suggestions for Improving Conflict of Interest Processes in the US Food and Drug Administration Advisory Committees-Past Imperfect

Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017

The US Food and Drug Administration's tentative approval process and the global fight against HIV.

Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.

US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs

Updated Estimates of Pharmaceutical Company Payments to Physicians in Vermont

Violations of exhibiting and FDA rules at an American Psychiatric Association annual meeting.